Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Abnormal Prenatal Blood Test Results Could Indicate Hidden Maternal Cancers

By LabMedica International staff writers
Posted on 05 Dec 2024

Researchers have discovered previously undiagnosed cancers in 48. More...

6% of pregnant individuals who received abnormal results from prenatal cell-free DNA (cfDNA) testing, which is typically used to screen for chromosomal disorders in the fetus. The types of cancers found included colorectal, breast, lung, and pancreatic cancers, as well as lymphoma, cholangiocarcinoma, and renal carcinoma. The cfDNA screening test analyzes placental DNA fragments circulating in the maternal bloodstream to identify an extra chromosome or determine the baby’s sex. In addition to detecting fetal DNA, cfDNA testing also identifies DNA released from the mother’s red blood stem cells, and occasionally, it can reveal abnormal DNA that may indicate an undiagnosed cancer in an asymptomatic pregnant individual. This study was published in the New England Journal of Medicine.

The ongoing IDENTIFY study by the National Institutes of Health (NIH, Bethesda, MD, USA) is investigating the implications of abnormal cfDNA test results that may suggest the presence of cancer. For the current analysis, the researchers screened 107 participants from the IDENTIFY study for cancer using whole-body magnetic resonance imaging (MRI), standard medical diagnostic tests, and cfDNA sequencing. Out of these participants, 52 were diagnosed with cancer. The researchers found that whole-body MRI was the most effective method for detecting cancer in this group.

Traditional diagnostic methods, such as reviewing medical history, assessing symptoms, and performing physical examinations, proved limited in detecting cancer or pinpointing its location. Other abnormal cfDNA results were found to be related to fibroids (benign tumors of the uterus), discrepancies between placental and fetal chromosomes, and clonal hematopoiesis in the mother (a precursor to blood cancers). The researchers emphasized the need for further studies to confirm the cfDNA sequencing patterns identified in this study, which could help detect cancer in pregnant individuals with no obvious clinical symptoms.


New
Gold Member
Collection and Transport System
PurSafe Plus®
Collection and Transport System
PurSafe Plus®
New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.